Scholar Rock Holding

SRRK · NASDAQ

$41.36+$1.12 (+2.78%)TodayMarket closed · Oct 20, 7:57 PM ET

Prev close $40.24

Latest news

Press releaseOct 20, 8:00 AM ETBusiness Wire
Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026
Press releaseOct 16, 4:15 PM ETBusiness Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseOct 8, 8:00 AM ETBusiness Wire
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
NewsOct 5, 8:41 AM ET
Scholar Rock Holding Reports Q2 2026 Results: Full Earnings Call Transcript
Press releaseSep 30, 9:56 AM ETPRNewswire
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
Press releaseSep 21, 12:00 PM ETBusiness Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsSep 14, 9:24 AM ETVandana Singh
Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
Press releaseSep 11, 6:25 PM ETBusiness Wire
Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
NewsSep 11, 5:23 PM ET
FDA Approves First Therapy To Target Muscle Loss In Spinal Muscular Atrophy In Patients Aged 2 Years And Older
Press releaseSep 2, 8:00 AM ETBusiness Wire
Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial
Press releaseAug 27, 8:00 AM ETBusiness Wire
Scholar Rock to Present at Upcoming Investor Conferences
NewsAug 21, 9:11 AM ET
Scholar Rock Removes Catalent Indiana As Commercial Fill-Finish Facility From Its Apitegromab BLA For The Treatment Of Spinal Muscular Atrophy Under Guidance From The FDA; Now On Track To Submit Apitegromab Japanese New Drug Application By End-2026
Press releaseAug 21, 9:06 AM ETBusiness Wire
Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan
Press releaseAug 14, 4:15 PM ETBusiness Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsAug 10, 12:03 PM ETVandana Singh
Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule
Press releaseAug 7, 4:20 PM ETBusiness Wire
Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date
Press releaseAug 6, 7:00 AM ETBusiness Wire
Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Press releaseJul 29, 8:00 AM ETBusiness Wire
Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference
Press releaseJul 28, 7:14 PM ETPRNewswire
Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
Press releaseJul 20, 8:00 AM ETBusiness Wire
Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)
Press releaseJul 17, 4:15 PM ETBusiness Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseJul 16, 8:00 AM ETBusiness Wire
Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026
Press releaseJun 22, 8:00 AM ETBusiness Wire
Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD
Press releaseJun 12, 4:15 PM ETBusiness Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseMay 26, 9:30 AM ETBusiness Wire
Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Press releaseMay 20, 8:00 AM ETBusiness Wire
Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference
Press releaseMay 15, 4:15 PM ETBusiness Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseMay 7, 7:00 AM ETBusiness Wire
Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights
Press releaseApr 29, 8:00 AM ETBusiness Wire
Scholar Rock to Present at the BofA Securities 2026 Health Care Conference
Press releaseApr 17, 4:15 PM ETBusiness Wire
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsMar 31, 9:57 AM ETAvi Kapoor
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
NewsMar 3, 7:04 AM ET
Scholar Rock Holding: Q4 Earnings Insights
NewsMar 3, 6:11 AM ET
Earnings Scheduled For March 3, 2026
NewsMar 2, 9:02 AM ET
Earnings Preview For Scholar Rock Holding
NewsNov 25, 10:14 AM ETVandana Singh
FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults
NewsNov 14, 9:54 AM ETAvi Kapoor
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday
NewsNov 14, 6:11 AM ET
Earnings Scheduled For November 14, 2025
NewsNov 13, 3:05 PM ETErica Kollmann
Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks
NewsNov 13, 9:01 AM ET
What to Expect from Scholar Rock Holding's Earnings

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock Holding Reports Q2 2026 Results: Full Earnings Call Transcript

Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

FDA Approves First Therapy To Target Muscle Loss In Spinal Muscular Atrophy In Patients Aged 2 Years And Older

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

Scholar Rock to Present at Upcoming Investor Conferences

Scholar Rock Removes Catalent Indiana As Commercial Fill-Finish Facility From Its Apitegromab BLA For The Treatment Of Spinal Muscular Atrophy Under Guidance From The FDA; Now On Track To Submit Apitegromab Japanese New Drug Application By End-2026

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026

Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock to Present at the BofA Securities 2026 Health Care Conference

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

Scholar Rock Holding: Q4 Earnings Insights

Earnings Scheduled For March 3, 2026

Earnings Preview For Scholar Rock Holding

FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults

Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday

Earnings Scheduled For November 14, 2025

Looking For A Squeeze? Here Are The Top 10 Most Shorted Stocks

What to Expect from Scholar Rock Holding's Earnings